Neurodegenerative diseases include a significant number of pathologies affecting the nervous system. Generally, the primary cause of each disease is specific; however, recently, it was shown that they may be correlated at molecular level. This aspect, together with the exhibition of similar symptoms, renders the diagnosis of these disorders difficult. Amyotrophic lateral sclerosis is one of these pathologies. Herein, we report several cases of amyotrophic lateral sclerosis misdiagnosed as a consequence of features that are common to several neurodegenerative diseases, such as Parkinson's, Huntington's and Alzheimer's disease, spinal muscular atrophy, progressive bulbar palsy, spastic paraplegia and frontotemporal dementia, and mostly with the lysosomal storage disorder GM2 gangliosidosis. Overall reports highlight that the differential diagnosis for amyotrophic lateral sclerosis should include correlated mechanisms.

Keywords:
Superoxide dismutase 1, Tay-Sachs disease, Alzheimer’s disease, Amyotrophic lateral sclerosis, Differential diagnosis, GM2 gangliosidosis, Misdiagnosis, Neurodegenerative disorders, Parkinson’s disease, Sandhoff disease
1.
Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
2.
Mutations in the copper- and zinc-containing superoxide dismutase gene are associated with ‘Lou Gehrig's disease'. Nutr Rev 1993;51:243-245.
3.
Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC: Amyotrophic lateral sclerosis. Lancet 2011;377:942-955.
4.
Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA: Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013;41:118-130.
5.
Hardiman O, van den Berg LH, Kiernan MC: Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011;7:639-649.
6.
Brooks BR: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ‘Clinical limits of amyotrophic lateral sclerosis' workshop contributors. J Neurol Sci 1994;124(suppl): 96-107.
7.
World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House ‘Therapeutic Trials in ALS' Workshop Contributors. J Neurol Sci 1995;129(suppl):1-10.
8.
Carvalho MD, Swash M: Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler 2009;10:53-57.
9.
Chiò A: ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol 1999; 246(suppl III):III1-III5.
10.
Cellura E, Spataro R, Taiello AC, La Bella V: Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg 2012;114:550-554.
11.
Rowland LP: Assisted suicide and alternatives in amyotrophic lateral sclerosis. N Engl J Med 1998;339:987-989.
12.
Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, Millul A, Benn E, Beghi E; EURALS: Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010;81:385-390.
13.
Gouveia LO, de Carvalho M: Young-onset sporadic amyotrophic lateral sclerosis: a distinct nosological entity? Amyotroph Lateral Scler 2007;8:323-327.
14.
Cleveland DW, Rothstein JD: From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2:806-819.
15.
Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T: TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;351:602-611.
16.
Ivanova MI, Sievers SA, Guenther EL, Johnson LM, Winkler DD, Galaleldeen A, Sawaya MR, Hart PJ, Eisenberg DS: Aggregation-triggering segments of SOD1 fibril formation support a common pathway for familial and sporadic ALS. Proc Natl Acad Sci USA 2014;111:197-201.
17.
Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M, Nakano I, Oda T, Tsuchiya K, Akiyama H: Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008;64:60-70.
18.
Restagno G, Lombardo F, Sbaiz L, Mari C, Gellera C, Alimonti D, Calvo A, Tarenzi L, Chiò A: The rare G93D mutation causes a slowly progressing lower motor neuron disease. Amyotroph Lateral Scler 2008;9:35-39.
19.
Gaudette M, Hirano M, Siddique T: Current status of SOD1 mutations in familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:83-89.
20.
Andersen PM, Sims KB, Xin WW, Kiely R, O'Neill G, Ravits J, Pioro E, Harati Y, Brower RD, Levine JS, Heinicke HU, Seltzer W, Boss M, Brown RH Jr: Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:62-73.
21.
Siddique T, Deng HX: Genetics of amyotrophic lateral sclerosis. Hum Mol Genet 1996;5:1465-1470.
22.
Kohno S, Takahashi Y, Miyajima H, Serizawa M, Mizoguchi K: A novel mutation (Cys6Gly) in the Cu/Zn superoxide dismutase gene associated with rapidly progressive familial amyotrophic lateral sclerosis. Neurosci Lett 1999;276:135-137.
23.
Rezania K, Yan J, Dellefave L, Deng HK, Siddique N, Pascuzzi RT, Siddique T, Roos RP: A rare Cu/Zn superoxide dismutase mutation causing familial amyotrophic lateral sclerosis with variable age of onset, incomplete penetrance and a sensory neuropathy. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:162-166.
24.
Shi SG, Li LS, Chen KN, Liu X: Identification of the mutation of SOD1 gene in a familial amyotrophic lateral sclerosis (in Chinese). Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2004;21:149-152.
25.
Nakamura A, Kuru S, Hineno A, Kobayashi C, Kinoshita T, Miyazaki D, Ikeda S: Slowly progressing lower motor neuron disease caused by a novel duplication mutation in exon 1 of the SOD1 gene. Neurobiol Aging 2014;35:2420.
26.
Pasinelli P, Brown RH: Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006;7:710-723.
27.
Zelko IN, Mariani TJ, Folz RJ: Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 2002;33:337-349.
28.
Pardo CA, Xu Z, Borchelt DR, Price DL, Sisodia SS, Cleveland DW: Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci USA 1995;92:954-958.
29.
Fukai T, Ushio-Fukai M: Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal 2011;15:1583-1606.
30.
Inoue E, Tano K, Yoshii H, Nakamura J, Tada S, Watanabe M, Seki M, Enomoto T: SOD1 is essential for the viability of DT40 cells and nuclear SOD1 functions as a guardian of genomic DNA. J Nucleic Acids 2010, DOI: 10.4061/2010/795946.
31.
Bourassa MW, Brown HH, Borchelt DR, Vogt S, Miller LM: Metal-deficient aggregates and diminished copper found in cells expressing SOD1 mutations that cause ALS. Front Aging Neurosci 2014;6:110.
32.
Tateno M, Kato S, Sakurai T, Nukina N, Takahashi R, Araki T: Mutant SOD1 impairs axonal transport of choline acetyltransferase and acetylcholine release by sequestering KAP3. Hum Mol Genet 2009;18:942-955.
33.
Paez-Gonzalez P, Asrican B, Rodriguez E, Kuo CT: Identification of distinct ChAT(+) neurons and activity-dependent control of postnatal SVZ neurogenesis. Nat Neurosci 2014;17:934-942.
34.
Cheroni C, Marino M, Tortarolo M, Veglianese P, De Biasi S, Fontana E, Zuccarello LV, Maynard CJ, Dantuma NP, Bendotti C: Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum Mol Genet 2009;18:82-96.
35.
Pradat PF, Dupuis L: ALS treatment: state of the art in 2014 and perspectives. Presse Med 2014;43:595-602.
37.
Mazzini L, Gelati M, Profico DC, Sgaravizzi G, Projetti Pensi M, et al: Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med 2015;13:17.
38.
Feldman EL, Boulis NM, Hur J, Johe K, Rutkove SB, Federici T, Polak M, Bordeau J, Sakowski SA, Glass JD: Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol 2014;75:363-373.
39.
Lincecum JM, Vieira FG, Wang MZ, Thompson K, De Zutter GS, Kidd J, Moreno A, Sanchez R, Carrion IJ, Levine BA, Al-Nakhala BM, Sullivan SM, Gill A, Perrin S: From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet 2010;42:392-399.
40.
Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, Carmeliet P, Mazarakis ND: VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004;429:413-417.
41.
Bicchi I, Morena F, Montesano S, Polidoro M, Martino S: MicroRNAs and molecular mechanisms of neurodegeneration. Genes (Basel) 2013;4:244-263.
42.
Martino S, Emiliani C, Tancini B, Severini GM, Chigorno V, Bordignon C, Sonnino S, Orlacchio A: Absence of cross-correction in Tay-Sachs cells: implication in gene therapy. J Biol Chem 2002;277:20177-20184.
43.
Martino S, Marconi P, Tancini B, Dolcetta D, Cusella De Angelis MG, Montanucci P, Bregola G, Sandhoff K, Bordignon C, Emiliani C, Manservigi R, Orlacchio A: A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease. Hum Mol Genet 2005;14:2113-2123.
44.
Martino S, di Girolamo I, Cavazzini C, Tiribuzi R, Galli R, Rivaroli A, Valsecchi M, Sandhoff K, Sonnino S, Vescovi A, Gritti A, Orlacchio A: Neural precursor cell cultures from GM2 gangliosidosis animal models recapitulate the biochemical and molecular hallmarks of the brain pathology. J Neurochem 2009;109:135-147.
45.
Mattoli F, Tiribuzi R, D'Angelo F, di Girolamo I, Quattrocelli M, Montesano S, Crispoltoni L, Oikonomou V, Cusella De Angelis MG, Marconi P, Orlacchio A, Sampaolesi M, Martino S, Orlacchio A: Development of a new tool for 3D modeling for regenerative medicine. Int J Biomed Imaging 2011;2011:236854.
46.
Martino S, Tiribuzi R, Tortori A, Conti D, Visigalli I, Lattanti A, Biffi A, Gritti A, Orlacchio A: Specific determination of β-galactocerebrosidase activity via competitive inhibition of β-galactosidase. Clin Chem 2009;55:541-548.
47.
Mitsumoto H, Sliman RJ, Schafer IA, Sternick CS, Kaufman B, Wilbourn A, Horwitz SJ: Motor neuron disease and adult hexosaminidase A (Hex A) deficiency in two families: evidence for multisystem degeneration. Ann Neurol 1985;17:378-385.
48.
Gudesblatt M, Ludman MD, Cohen JA, Desnick RJ, Chester S, Grabowski GA, Caroscio JT: Hexosaminidase A activity and amyotrophic lateral sclerosis. Muscle Nerve 1988;11:227-230.
49.
Drory VE, Birnbaum M, Peleg L, Goldman B, Korczyn AD: Hexosaminidase A deficiency is an uncommon cause of a syndrome mimicking amyotrophic lateral sclerosis. Muscle Nerve 2003;28:109-112.
50.
Pierson TM, Torres PA, Zeng BJ, Glanzman AM, Adams D, Finkel RS, Mahuran DJ, Pastores GM, Tennekoon GI, Kolodny EH: Juvenile-onset motor neuron disease caused by novel mutations in β-hexosaminidase. Mol Genet Metab 2013;108:65-69.
51.
Wakamatsu N, Kobayashi H, Miyatake T, Tsuji S: A novel exon mutation in the human beta-hexosaminidase beta subunit gene affects 3′ splice site selection. J Biol Chem 1992;267:2406-2413.
52.
Yamada K, Takado Y, Kato YS, Yamada Y, Ishiguro H, Wakamatsu N: Characterization of the mutant β-subunit of β-hexosaminidase for dimer formation responsible for the adult form of Sandhoff disease with the motor neuron disease phenotype. J Biochem 2013;153:111-119.
53.
Takado Y, Koide T, Yoshikawa K, Amaya N, Yoshida Y, Ishiguro H: A patient with GM2 gangliosidosis presenting with motor neuron disease symptom in his forties (in Japanese). Rinsho Shinkeigaku 2007;47:37-41.
54.
van Es MA, Schelhaas HJ, van Vught PW, Ticozzi N, Andersen PM, et al: Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol 2011;70:964-973.
55.
Wang X, Blanchard J, Grundke-Iqbal I, Wegiel J, Deng HX, Siddique T, Iqbal K: Alzheimer disease and amyotrophic lateral sclerosis: an etiopathogenic connection. Acta Neuropathol 2014;127:243-256.
56.
Shang H, Liu G, Jiang Y, Fu J, Zhang B, Song R, Wang W: Pathway analysis of two amyotrophic lateral sclerosis GWAS highlights shared genetic signals with Alzheimer's disease and Parkinson's disease. Mol Neurobiol 2014;51:361-369.
57.
Martino S, Cavalieri C, Emiliani C, Dolcetta D, Cusella De Angelis MG, Chigorno V, Severini GM, Sandhoff K, Bordignon C, Sonnino S, Orlacchio A: Restoration of the GM2 ganglioside metabolism in bone marrow-derived stromal cells from Tay-Sachs disease animal model. Neurochem Res 2002;27:793-800.
58.
Neri M, Ricca A, di Girolamo I, Alcalò-Franco B, Cavazzin C, Orlacchio A, Martino S, Naldini L, Gritti A: Neural stem cell gene therapy ameliorates pathology and function in a mouse model of globoid cell leukodystrophy. Stem Cells 2011;29:1559-1571.
59.
Tiribuzi R, D'Angelo F, Berardi AC, Martino S, Orlacchio A: Knock-down of HEXA and HEXB genes correlate with the absence of the immunostimulatory function of HSC-derived dendritic cells. Cell Biochem Funct 2012;30:61-68.
60.
Santambrogio S, Ricca A, Maderna C, Ieraci A, Aureli M, et al: The galactocerebrosidase enzyme contributes to maintain a functional neurogenic niche during early post-natal CNS development. Hum Mol Genet 2012;21:4732-4750.
61.
Martino S, Montesano S, di Girolamo I, Tiribuzi R, Di Gregorio M, Orlacchio A, Datti A, Calabresi P, Sarchielli P, Orlacchio A: Expression of cathepsins S and D signals a distinctive biochemical trait in CD34+ hematopoietic stem cells of relapsing-remitting multiple sclerosis patients. Mult Scler 2013;11:1443-1453.
62.
Morena F, di Girolamo I, Emiliani C, Gritti A, Biffi A, Martino S: A new analytical bench assay for the determination of arylsulfatase A activity toward galactosyl-3-sulfate ceramide: implication for metachromatic leukodystrophy diagnosis. Anal Chem 2014;86:473-481.
63.
Lorioli L, Cesani M, Regis S, Morena F, Grossi S, Fumagalli F, Acquati S, Redaelli D, Pini A, Sessa M, Martino S, Filocamo M, Biffi A: Critical issues for the proper diagnosis of metachromatic leukodystrophy. Gene 2014;537:348-351.
64.
Lattanzi A, Salvagno C, Maderna C, Benedicenti F, Morena F, Kulik W, Naldini L, Montini E, Martino S, Gritti A: Therapeutic benefit of lentiviral-mediated neonatal intracerebral gene therapy in a mouse model of globoid cell leukodystrophy. Hum Mol Genet 2014;23:3250-3268.
65.
Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, et al: Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013;341:1233158.
66.
Nixon RA: The role of autophagy in neurodegenerative disease. Nat Med 2013;19:983-997.
67.
Kikuchi H, Yamada T, Furuya H, Doh-ura K, Ohyagi Y, Iwaki T, Kira J: Involvement of cathepsin B in the motor neuron degeneration of amyotrophic lateral sclerosis. Acta Neuropathol 2003;105:462-468.
68.
Shachar T, Lo Bianco C, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH: Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov Disord 2011;26:1593-1604.
69.
Lesage S, Anheim M, Condroyer C, Pollak P, Durif F, Dupuits C, Viallet F, Lohmann E, Corvol JC, Honoré A, Rivaud S, Vidailhet M, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group: Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet 2011;20:202-210.
70.
Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D: Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37-52.
71.
Crabtree D, Dodson M, Ouyang X, Boyer-Guittaut M, Liang Q, Ballestas ME, Fineberg N, Zhang J: Over-expression of an inactive mutant cathepsin D increases endogenous alpha-synuclein and cathepsin B activity in SH-SY5Y cells. J Neurochem 2014;128:950-961.
72.
van Dijk KD, Persichetti E, Chiasserini D, Eusebi P, Beccari T, Calabresi P, Berendse HW, Parnetti L, van de Berg WD: Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. Mov Disord 2013;28:747-754.
73.
Tiribuzi R, Orlacchio A, Crispoltoni L, Maiotti M, Zampolini M, De Angeliz M, Mecocci P, Cecchetti R, Bernardi G, Datti A, Martino S, Orlacchio A: Lysosomal β-galactosidase and β-hexosaminidase activities correlate with clinical stages of dementia associated with Alzheimer's disease and type 2 diabetes mellitus. J Alzheimers Dis 2011;24:785-797.
74.
McBrayer M, Nixon RA: Lysosome and calcium dysregulation in Alzheimer's disease: partners in crime. Biochem Soc Trans 2013;41:1495-1502.
75.
Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA: Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 2010;141:1146-1158.
76.
Annunziata I, Patterson A, Helton D, Hu H, Moshiach S, Gomero E, Nixon R, d'Azzo A: Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-β secretion via deregulated lysosomal exocytosis. Nat Commun 2013;4:2734.
77.
Emiliani C, Urbanelli L, Racanicchi L, Orlacchio A, Pelicci G, Sorbi S, Bernardi G, Orlacchio A: Up-regulation of glycohydrolases in Alzheimer's disease fibroblasts correlates with Ras activation. J Biol Chem 2003;278:38453-38460.
78.
Magini A, Urbanelli L, Ciccarone V, Tancini B, Polidoro M, Timperio AM, Zolla L, Tedde A, Sorbi S, Emiliani C: Fibroblasts from PS1 mutated pre-symptomatic subjects and Alzheimer's disease patients share a unique protein levels profile. J Alzheimers Dis 2010;21:431-444.
79.
Rubio A, Steinberg K, Figlewicz DA, MacDonald ME, Greenamyre T, Hamill R, Shoulson I, Powers JM: Coexistence of Huntington's disease and familial amyotrophic lateral sclerosis: case presentation. Acta Neuropathol 1996;92:421-427.
80.
Papageorgiou SG, Antelli A, Bonakis A, Vassos E, Zalonis I, Kalfakis N, Panas M: Association of genetically proven Huntington's disease and sporadic amyotrophic lateral sclerosis in a 72-year-old woman. J Neurol 2006;253:1649-1650.
81.
Sadeghian H, O'Suilleabhain PE, Battiste J, Elliott JL, Trivedi JR: Huntington chorea presenting with motor neuron disease. Arch Neurol 2011;68:650-652.
82.
Tada M, Coon EA, Osmand AP, Kirby PA, Martin W, Wieler M, Shiga A, Shirasaki H, Tada M, Makifuchi T, Yamada M, Kakita A, Nishizawa M, Takahashi H, Paulson HL: Coexistence of Huntington's disease and amyotrophic lateral sclerosis: a clinicopathologic study. Acta Neuropathol 2012;124:749-760.
83.
Praline J, Guennoc AM, Vourc'h P, Sedel F, Andres CR, Corcia P: Late onset Tay-Sachs disease may mimic adult SMA (in French). Rev Neurol (Paris) 2011;167:549-550.
84.
Deik A, Saunders-Pullman R: Atypical presentation of late-onset Tay-Sachs disease. Muscle Nerve 2014;49:768-771.
85.
Jamrozik Z, Lugowska A, Gołębiowski M, Królicki L, Mączewska J, Kuźma-Kozakiewicz M: Late onset GM2 gangliosidosis mimicking spinal muscular atrophy. Gene 2013;527:679-682.
86.
Neudorfer O, Pastores GM, Zeng BJ, Gianutsos J, Zaroff CM, Kolodny EH: Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med 2005;7:119-123.
87.
Noto Y, Misawa S, Kanai K, Shibuya K, Isose S, Nasu S, Sekiguchi Y, Fujimaki Y, Nakagawa M, Kuwabara S: Awaji ALS criteria increase the diagnostic sensitivity in patients with bulbar onset. Clin Neurophysiol 2012;123:382-385.
88.
Wishik J (eds): Medical and Legal Aspects of Neurology. Tucson, Lawyers & Judges, 2005.
89.
Orlacchio A, Babalini C, Borreca A, Patrono C, Massa R, Basaran S, Munhoz RP, Rogaeva EA, St George-Hyslop PH, Bernardi G, Kawarai T: SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain 2010;133:591-598.
90.
Meyer T, Schwan A, Dullinger JS, Brocke J, Hoffmann KT, Nolte CH, Hopt A, Kopp U, Andersen P, Epplen JT, Linke P: Early-onset ALS with long-term survival associated with spastin gene mutation. Neurology 2005;65:141-143.
91.
Lomen-Hoerth C: Clinical phenomenology and neuroimaging correlates in ALS-FTD. J Mol Neurosci 2011;45:656-662.
92.
Kiernan MC: Amyotrophic lateral sclerosis and frontotemporal dementia. J Neurol Neurosurg Psychiatry 2012;83:355.
93.
Gascon E, Gao FB: The emerging roles of microRNAs in the pathogenesis of frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) spectrum disorders. J Neurogenet 2014;28:30-40.
94.
Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al: A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-268.
95.
Nzwalo H, de Abreu D, Swash M, Pinto S, de Carvalho M: Delayed diagnosis in ALS: the problem continues. J Neurol Sci 2014;343:173-175.
96.
Sun S, Ling SC, Qiu J, Albuquerque CP, Zhou Y, Tokunaga S, Li H, Qiu H, Bui A, Yeo GW, Huang EJ, Eggan K, Zhou H, Fu XD, Lagier-Tourenne C, Cleveland DW: ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP. Nat Commun 2015;6:6171.
97.
Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, Dardis A, Deganuto M, De Carlo C, Castrioto A, Balducci C, Paciotti S, Tambasco N, Bembi B, Bonanni L, Onofrj M, Rossi A, Beccari T, El-Agnaf O, Calabresi P: Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord 2014;29:1019-1027.
98.
Tiribuzi R, Orlacchio A, Crispoltoni L, Maiotti M, Zampolini M, De Angeliz M, Mecocci P, Cecchetti R, Bernardi G, Datti A, Martino S, Orlacchio A: Lysosomal β-galactosidase and β-hexosaminidase activities correlate with clinical stages of dementia associated with Alzheimer's disease and type 2 diabetes mellitus. J Alzheimers Dis 2011;24:785-797.
99.
Watabe-Rudolph M, Song Z, Lausser L, Schnack C, Begus-Nahrmann Y, Scheithauer MO, Rettinger G, Otto M, Tumani H, Thal DR, Attems J, Jellinger KA, Kestler HA, von Arnim CA, Rudolph KL: Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology 2012;78:569-577.
100.
Guerreiro R, Brás J, Hardy J: SnapShot: genetics of ALS and FTD. Cell 2015;160:798-798.
101.
Rohrer JD, Isaacs AM, Mizielinska S, Mead S, Lashley T, Wray S, Sidle K, Fratta P, Orrell RW, Hardy J, Holton J, Revesz T, Rossor MN, Warren JD: C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol 2015;14:291-301.
102.
Nordin A, Akimoto C, Wuolikainen A, Alstermark H, Jonsson P, Birve A, Marklund SL, Graffmo KS, Forsberg K, Brännström T, Andersen PM: Extensive size variability of the GGGGCC-expansion in C9orf72 in both neuronal and non-neuronal tissue in 18 patients with ALS or FTD. Hum Mol Genet 2015;24:3133-3142.
103.
Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, Jaffa M, Milburn MV, Ryals JA, Bowser R, Cudkowicz ME, Berry JD; Northeast ALS Consortium: Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:362-370.
104.
Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, et al: Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015;347:1436-1441.
105.
Repnik U, Česen MH, Turk B: The endolysosomal system in cell death and survival. Cold Spring Harb Perspect Biol 2013;5:a008755.
106.
Giordano S, Darley-Usmar V, Zhang J: Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol 2013;2:82-90.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.